The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

Brigatinib (AP26113) is a dimethylphosphine oxide group-containing tyrosine kinase inhibitor (TKI) constructed around a bisanilinopyrimidine scaffold with potent activity against the anaplastic lymphoma kinase (ALK) and several other targets. Despite the activity of first- and second-generation ALK...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Onco Targets Ther
Glavni autori: Sabari, Joshua K, Santini, Fernando C, Schram, Alison M, Bergagnini, Isabella, Chen, Ruqin, Mrad, Chebli, Lai, W Victoria, Arbour, Kathryn C, Drilon, Alexander
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2017
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388194/
https://ncbi.nlm.nih.gov/pubmed/28435288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S109295
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items